| A Polycythemia Vera Updated: Diagnosis, Pathobiology, and Treatment. | |
| | |
MedLine Citation:
|
PMID: 11701535 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
This review focuses on polycythemia vera (PV)-its diagnosis, cellular and genetic pathology, and management. In Section I, Dr. Pearson, with Drs. Messinezy and Westwood, reviews the diagnostic challenge of the investigation of patients with a raised hematocrit. The suggested approach divides patients on their red cell mass (RCM) results into those with absolute (raised RCM) and apparent (normal RCM) erythrocytosis. A standardized series of investigations is proposed for those with an absolute erythrocytosis to confirm the presence of a primary (PV) or secondary erythrocytosis, with abnormal and normal erythropoietic compartments respectively, leaving a heterogenous group, idiopathic erythrocytosis, where the cause cannot be established. Since there is no single diagnostic test for PV, its presence is confirmed following the use of updated diagnostic criteria and confirmatory marrow histology. In Section II, Dr. Green with Drs. Bench, Huntly, and Nacheva reviews the evidence from studies of X chromosome inactivation patterns that support the concept that PV results from clonal expansion of a transformed hemopoietic stem cell. Analyses of the pattern of erythroid and myeloid colony growth have demonstrated abnormal responses to several cytokines, raising the possibility of a defect in a signal transduction pathway shared by several growth factors. A number of cytogenetic and molecular approaches are now focused on defining the molecular lesion(s). In the last section, Dr. Barbui with Dr. Finazzi addresses the complications of PV, notably thrombosis, myelofibrosis and acute leukemia. Following an evaluation of published data, a management approach is proposed. All patients should undergo phlebotomy to keep the hematocrit (Hct) below 0.45, which may be all that is required in those at low thrombotic risk and with stable disease. In those at high thrombotic risk or with progressive thrombocytosis or splenomegaly, a myelosuppressive agent should be used. Hydroxyurea has a role at all ages, but (32)P or busulfan may be used in the elderly. In younger patients, interferon-alpha or anagrelide should be considered. Low-dose aspirin should be used in those with thrombotic or ischemic complications. |
| | |
Authors:
|
Thomas C. Pearson; Maria Messinezy; Nigel Westwood; Anthony R. Green; Anthony J. Bench; Anthony R. Green; Brian J.P. Huntly; Elizabeth P. Nacheva; Tiziano Barbui; Guido Finazzi |
Related Documents
:
|
15370215 - Central nervous system relapse in two patients with chronic myelogenous leukemia in mye... 1071475 - Behaviour of leukocyte acid phosphatase in various chronic diseases. 8971385 - Detection of occasional and clonal chromosome aberrations in patients with acute non-ly... 12901975 - The emergence of ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treat... 10780695 - Eccentric compression of the spinal canal causing dominantly contralateral-side symptoms. 17713765 - The efficacy of whole-body fdg-pet or pet/ct for autoimmune pancreatitis and associated... |
Publication Detail:
|
Type: JOURNAL ARTICLE |
Journal Detail:
|
Title: Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program Volume: - ISSN: 1520-4383 ISO Abbreviation: Hematology Am Soc Hematol Educ Program Publication Date: 2000 |
Date Detail:
|
Created Date: 2001-Nov-9 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100890099 Medline TA: Hematology Am Soc Hematol Educ Program Country: - |
Other Details:
|
Languages: ENG Pagination: 51-68 Citation Subset: - |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Clinical Consequences of New Insights in the Pathophysiology of Disorders of Iron and Heme Metabolis...
Next Document: New Developments in the Therapy of Acute Myelocytic Leukemia.